Doxorubicin, mitomycin C and 5-fluorouracil in the treatment of hormone refractory adenocarcinoma of the prostate: A Southwest Oncology Group study

B. Blumenstein; E. D. Crawford; J. H. Saiers; R. L. Stephens; S. E. Rivkin; C. A. Coltman

doi:10.1016/S0022-5347(17)35496-4

Doxorubicin, mitomycin C and 5-fluorouracil in the treatment of hormone refractory adenocarcinoma of the prostate: A Southwest Oncology Group study

B. Blumenstein, E. D. Crawford, J. H. Saiers, R. L. Stephens, S. E. Rivkin, C. A. Coltman

Research output: Contribution to journal › Article › peer-review

23 Scopus citations

Abstract

In a Southwest Oncology Group phase II clinical trial, 68 patients with hormone refractory carcinoma of the prostate were treated with a combination of doxorubicin, mitomycin C and 5-fluorouracil. Of the patients 11 were classified as good risk and 57 as poor risk. There were 1 complete and 10 partial remissions for a response rate of 16.2% (exact 95% confidence interval 8.4 to 27.1%). Median survival was 9 months (maximum 14) for good risk patients and 10 months (maximum 42) for poor risk patients. Toxicity was significant with leukopenia identified as dose limiting. Because of the low rate of response and significant toxicity, this regimen cannot be recommended as standard therapy for metastatic hormone refractory prostate cancer.

Original language	English (US)
Pages (from-to)	411-413
Number of pages	3
Journal	Journal of Urology
Volume	150
Issue number	2
DOIs	https://doi.org/10.1016/S0022-5347(17)35496-4
State	Published - 1993
Externally published	Yes

Keywords

clinical trials
drug therapy
prostatic neoplasms

ASJC Scopus subject areas

Urology

Access to Document

10.1016/S0022-5347(17)35496-4

Cite this

@article{c62e925743ab4bb4b5d0ded7853c9c7a,

title = "Doxorubicin, mitomycin C and 5-fluorouracil in the treatment of hormone refractory adenocarcinoma of the prostate: A Southwest Oncology Group study",

abstract = "In a Southwest Oncology Group phase II clinical trial, 68 patients with hormone refractory carcinoma of the prostate were treated with a combination of doxorubicin, mitomycin C and 5-fluorouracil. Of the patients 11 were classified as good risk and 57 as poor risk. There were 1 complete and 10 partial remissions for a response rate of 16.2% (exact 95% confidence interval 8.4 to 27.1%). Median survival was 9 months (maximum 14) for good risk patients and 10 months (maximum 42) for poor risk patients. Toxicity was significant with leukopenia identified as dose limiting. Because of the low rate of response and significant toxicity, this regimen cannot be recommended as standard therapy for metastatic hormone refractory prostate cancer.",

keywords = "clinical trials, drug therapy, prostatic neoplasms",

author = "B. Blumenstein and Crawford, {E. D.} and Saiers, {J. H.} and Stephens, {R. L.} and Rivkin, {S. E.} and Coltman, {C. A.}",

year = "1993",

doi = "10.1016/S0022-5347(17)35496-4",

language = "English (US)",

volume = "150",

pages = "411--413",

journal = "Investigative Urology",

issn = "0022-5347",

publisher = "Elsevier Inc.",

number = "2",

}

TY - JOUR

T1 - Doxorubicin, mitomycin C and 5-fluorouracil in the treatment of hormone refractory adenocarcinoma of the prostate

T2 - A Southwest Oncology Group study

AU - Blumenstein, B.

AU - Crawford, E. D.

AU - Saiers, J. H.

AU - Stephens, R. L.

AU - Rivkin, S. E.

AU - Coltman, C. A.

PY - 1993

Y1 - 1993

N2 - In a Southwest Oncology Group phase II clinical trial, 68 patients with hormone refractory carcinoma of the prostate were treated with a combination of doxorubicin, mitomycin C and 5-fluorouracil. Of the patients 11 were classified as good risk and 57 as poor risk. There were 1 complete and 10 partial remissions for a response rate of 16.2% (exact 95% confidence interval 8.4 to 27.1%). Median survival was 9 months (maximum 14) for good risk patients and 10 months (maximum 42) for poor risk patients. Toxicity was significant with leukopenia identified as dose limiting. Because of the low rate of response and significant toxicity, this regimen cannot be recommended as standard therapy for metastatic hormone refractory prostate cancer.

AB - In a Southwest Oncology Group phase II clinical trial, 68 patients with hormone refractory carcinoma of the prostate were treated with a combination of doxorubicin, mitomycin C and 5-fluorouracil. Of the patients 11 were classified as good risk and 57 as poor risk. There were 1 complete and 10 partial remissions for a response rate of 16.2% (exact 95% confidence interval 8.4 to 27.1%). Median survival was 9 months (maximum 14) for good risk patients and 10 months (maximum 42) for poor risk patients. Toxicity was significant with leukopenia identified as dose limiting. Because of the low rate of response and significant toxicity, this regimen cannot be recommended as standard therapy for metastatic hormone refractory prostate cancer.

KW - clinical trials

KW - drug therapy

KW - prostatic neoplasms

UR - http://www.scopus.com/inward/record.url?scp=0027179081&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027179081&partnerID=8YFLogxK

U2 - 10.1016/S0022-5347(17)35496-4

DO - 10.1016/S0022-5347(17)35496-4

M3 - Article

C2 - 8326565

AN - SCOPUS:0027179081

VL - 150

SP - 411

EP - 413

JO - Investigative Urology

JF - Investigative Urology

SN - 0022-5347

IS - 2

ER -

Doxorubicin, mitomycin C and 5-fluorouracil in the treatment of hormone refractory adenocarcinoma of the prostate: A Southwest Oncology Group study

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this